The effect of reboxetine in the treatment of depression in children and adolescents
Background: Depressive disorders in children and adolescents are chronic and highly morbid. Few studies are carried out on antidepressant drugs for depressed youths, especially specific noradrenergic agents. Reboxetine is a selective norepinephrine reuptake inhibitor. This study was designed to eval...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | fas |
| Published: |
Tehran University of Medical Sciences
2007-10-01
|
| Series: | Tehran University Medical Journal |
| Subjects: | |
| Online Access: | http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/4206.pdf&manuscript_id=4206 |
| _version_ | 1818917349369053184 |
|---|---|
| author | Tashakori A. Arabgol F. Panaghi L. Davari R. |
| author_facet | Tashakori A. Arabgol F. Panaghi L. Davari R. |
| author_sort | Tashakori A. |
| collection | DOAJ |
| description | Background: Depressive disorders in children and adolescents are chronic and highly morbid. Few studies are carried out on antidepressant drugs for depressed youths, especially specific noradrenergic agents. Reboxetine is a selective norepinephrine reuptake inhibitor. This study was designed to evaluate the effect of reboxetine in childhood and adolescent depression. Methods: Twenty patients of both genders, aged 7-17 years old, with major depressive or dysthymic disorders, as classified by the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), participated in an 8-week clinical trial before-after study of reboxetine. Clinical semistructured interviews, based on the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Aged Children (K-SADS), were carried out. Reboxtine was initiated at a dose of 1 mg/day and increased up to 6 mg/day. Patients were assessed for changes in: depressive symptoms using the Children's Depression Inventory (CDI) and global functioning by the Children's Global Assessment Scale (C-GAS). Side effect questionnaire was also administered. Results: There was a significant decrease in the ineffectiveness subscale (C factor) of CDI (p=0.006). Although the CDI scores decreased by 32.69%, this change was not significant (p=0.39). No significant change in C-GAS (p=0.2) was observed. Adverse effects were relatively mild to moderate and transient. The most common adverse effects were decreased appetite and sedation. Conclusions: Reboxetine is relatively well tolerated and improves feelings of ineffectiveness among depressed children and adolescents; however it does not improve all depressive symptoms. Double-blind, placebo and active comparator controlled studies and larger sample sizes are indicated. |
| first_indexed | 2024-12-20T00:32:39Z |
| format | Article |
| id | doaj.art-5093dd9f77304ab1ad03f2e795daffbe |
| institution | Directory Open Access Journal |
| issn | 1683-1764 1735-7322 |
| language | fas |
| last_indexed | 2024-12-20T00:32:39Z |
| publishDate | 2007-10-01 |
| publisher | Tehran University of Medical Sciences |
| record_format | Article |
| series | Tehran University Medical Journal |
| spelling | doaj.art-5093dd9f77304ab1ad03f2e795daffbe2022-12-21T19:59:52ZfasTehran University of Medical SciencesTehran University Medical Journal1683-17641735-73222007-10-016584048The effect of reboxetine in the treatment of depression in children and adolescentsTashakori A.Arabgol F.Panaghi L.Davari R.Background: Depressive disorders in children and adolescents are chronic and highly morbid. Few studies are carried out on antidepressant drugs for depressed youths, especially specific noradrenergic agents. Reboxetine is a selective norepinephrine reuptake inhibitor. This study was designed to evaluate the effect of reboxetine in childhood and adolescent depression. Methods: Twenty patients of both genders, aged 7-17 years old, with major depressive or dysthymic disorders, as classified by the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), participated in an 8-week clinical trial before-after study of reboxetine. Clinical semistructured interviews, based on the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Aged Children (K-SADS), were carried out. Reboxtine was initiated at a dose of 1 mg/day and increased up to 6 mg/day. Patients were assessed for changes in: depressive symptoms using the Children's Depression Inventory (CDI) and global functioning by the Children's Global Assessment Scale (C-GAS). Side effect questionnaire was also administered. Results: There was a significant decrease in the ineffectiveness subscale (C factor) of CDI (p=0.006). Although the CDI scores decreased by 32.69%, this change was not significant (p=0.39). No significant change in C-GAS (p=0.2) was observed. Adverse effects were relatively mild to moderate and transient. The most common adverse effects were decreased appetite and sedation. Conclusions: Reboxetine is relatively well tolerated and improves feelings of ineffectiveness among depressed children and adolescents; however it does not improve all depressive symptoms. Double-blind, placebo and active comparator controlled studies and larger sample sizes are indicated.http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/4206.pdf&manuscript_id=4206Children and adolescentsreboxetine |
| spellingShingle | Tashakori A. Arabgol F. Panaghi L. Davari R. The effect of reboxetine in the treatment of depression in children and adolescents Tehran University Medical Journal Children and adolescents reboxetine |
| title | The effect of reboxetine in the treatment of depression in children and adolescents |
| title_full | The effect of reboxetine in the treatment of depression in children and adolescents |
| title_fullStr | The effect of reboxetine in the treatment of depression in children and adolescents |
| title_full_unstemmed | The effect of reboxetine in the treatment of depression in children and adolescents |
| title_short | The effect of reboxetine in the treatment of depression in children and adolescents |
| title_sort | effect of reboxetine in the treatment of depression in children and adolescents |
| topic | Children and adolescents reboxetine |
| url | http://journals.tums.ac.ir/PdfMed.aspx?pdf_med=/upload_files/pdf/4206.pdf&manuscript_id=4206 |
| work_keys_str_mv | AT tashakoria theeffectofreboxetineinthetreatmentofdepressioninchildrenandadolescents AT arabgolf theeffectofreboxetineinthetreatmentofdepressioninchildrenandadolescents AT panaghil theeffectofreboxetineinthetreatmentofdepressioninchildrenandadolescents AT davarir theeffectofreboxetineinthetreatmentofdepressioninchildrenandadolescents AT tashakoria effectofreboxetineinthetreatmentofdepressioninchildrenandadolescents AT arabgolf effectofreboxetineinthetreatmentofdepressioninchildrenandadolescents AT panaghil effectofreboxetineinthetreatmentofdepressioninchildrenandadolescents AT davarir effectofreboxetineinthetreatmentofdepressioninchildrenandadolescents |